(3R,4R,5S)-4-acetamido-5-(ethylamino)-3-pentan-3-yloxycyclohexene-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3R,4R,5S)-4-acetamido-5-(ethylamino)-3-pentan-3-yloxycyclohexene-1-carboxylic acid
• 化学式: C₁₆H₂₈N₂O₄
• 分子量: 312.4
• InChiKey: BRZVPXOTOYXCTI-RRFJBIMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  87.7
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Platelet Additive Solution Having a beta-Galactosidase Inhibitor
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：US20140099629A1

  公开（公告）日：2014-04-10

  The present invention relates to a platelet additive solution (PAS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.
• NMR-BASED METABOLITE SCREENING PLATFORM
  申请人：THE CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US20150005243A1

  公开（公告）日：2015-01-01

  Methods that enable one to specifically measure the metabolic product of a particular molecule in relatively few cells, e.g. primary cells, are described. The methods involve optionally preloading cells with labeled substrate (e.g. labeled by 13 C, 15 N, or 31 P). The methods allow for easy identification of metabolites that are differentially generated in cells of different phenotypes. The new methods for unbiased multi-dimensional NMR screening and rapid and efficient analysis of the NMR screening identify differentially expressed metabolites in different cell or tissue types. Analysis of the differentially expressed metabolites can present unique druggable targets to which small molecule therapeutics can be designed.
• COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160030518A1

  公开（公告）日：2016-02-04

  The present disclosure provides methods of inhibiting viral activity in a cell, the methods generally involving contacting the cell with a soluble CD137 polypeptide or a FAM3C polypeptide. The present disclosure provides methods for treating a virus infection in an individual, the methods generally involving administering to the individual an effective amount of a soluble CD137 polypeptide or a FAM3C polypeptide.
• Platelet Protection Solution Having Beta-Galactosidase and Sialidase Inhibitors
  申请人：Velico Medical, Inc.

  公开号：US20160143269A1

  公开（公告）日：2016-05-26

  The present invention relates to a platelet protection solution (PPS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PPS components that include a salt, a citrate source, a carbon source, or any combination thereof.
• US9609861B2
  申请人：——

  公开号：US9609861B2

  公开（公告）日：2017-04-04